$CSDX OTCQB-CSDX Appoints Lachman Consultants for
Post# of 25469
(Total Views: 69)
Posted On: 03/12/2025 9:26:26 AM
$CSDX OTCQB-CSDX Appoints Lachman Consultants for CS-Protect Hydrogel FDA Approval
https://www.accessnewswire.com/newsroom/en/he...-ap-999007
CS DIAGNOSTICS CORP. ANNOUNCES THE APPOINTMENT OF FDA CONSULTANTS
Innovative tissue spacer technology for cancer radiology treatments
CHEYENNE, WY / ACCESS Newswire / March 12, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) (or "the company"
is delighted to announce the appointment of Lachman Consultants Inc., Westbury, NY www.lachmanconsultants.com to provide its regulatory expertise and support in the company's effort to acquire FDA approval for its CS-Protect Hydrogel.
CS-Protect Hydrogel is an organ spacer medical device that requires registration or approval from the respective governmental authorities, in particular the Food and Drug Administration (FDA) in the USA. Unlike the previous products, CS-Protect Hydrogelis more versatile and can also be used in other pathologies. CS-Protect Hydrogelis an advanced technology from molecular structure, chemical physical properties and medical applications. Registration was preceded by a testing procedure. CS Diagnostics Corp. anticipates a period of 3 to 4 months for approval in the U.S. Market.
Since 1978, Lachman Consultants have furnished expert compliance, regulatory affairs and technical services to clients around the world helping avoid and resolve compliance problems, assisting in the development of efficient and effective strategies for the submission, and approval of drugs and devices. Lachman Consultants serves all areas of global regulatory compliance-related activities for the Pharmaceutical, Biotechnology, Biologics, CGT, Device and Allied Health Industries.
Thomas Fahrhoefer, President of the Board at CS Diagnostics Corp., added:
" The Easy application of the CS-Protect Hydrogel being a ready-to-use product after removal from sterile packaging and unrequired further work steps eliminates any risk of contamination due to preparation and assembly of the product exclusion of another hygienic risk area within the treatment room. Also, no risk of wrong mixture especially wrong sequence and therefore no potential patient's missed treatments. "
Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:
" The predecessor product was acquired by Boston Scientific for $ 500 million (https://news.bostonscientific.com/2018-10-16-Boston-Scientific-Closes-Acquisition-of-Augmenix-Inc). We project the start of the production of CS-Protect Hydrogel in the U.S. market towards the first quarter of 2026."
Looking toward the future, CS Diagnostics Corp. is positioning itself for long-term growth with breakthrough innovations. As a listed entity on OTCQB, CS Diagnostics Corp. provides U.S. investors with access to a high-growth opportunity, ensuring long-term shareholder value by creating and executing impactful, market-leading solutions.
https://www.accessnewswire.com/newsroom/en/he...-ap-999007
CS DIAGNOSTICS CORP. ANNOUNCES THE APPOINTMENT OF FDA CONSULTANTS
Innovative tissue spacer technology for cancer radiology treatments
CHEYENNE, WY / ACCESS Newswire / March 12, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) (or "the company"
is delighted to announce the appointment of Lachman Consultants Inc., Westbury, NY www.lachmanconsultants.com to provide its regulatory expertise and support in the company's effort to acquire FDA approval for its CS-Protect Hydrogel. CS-Protect Hydrogel is an organ spacer medical device that requires registration or approval from the respective governmental authorities, in particular the Food and Drug Administration (FDA) in the USA. Unlike the previous products, CS-Protect Hydrogelis more versatile and can also be used in other pathologies. CS-Protect Hydrogelis an advanced technology from molecular structure, chemical physical properties and medical applications. Registration was preceded by a testing procedure. CS Diagnostics Corp. anticipates a period of 3 to 4 months for approval in the U.S. Market.
Since 1978, Lachman Consultants have furnished expert compliance, regulatory affairs and technical services to clients around the world helping avoid and resolve compliance problems, assisting in the development of efficient and effective strategies for the submission, and approval of drugs and devices. Lachman Consultants serves all areas of global regulatory compliance-related activities for the Pharmaceutical, Biotechnology, Biologics, CGT, Device and Allied Health Industries.
Thomas Fahrhoefer, President of the Board at CS Diagnostics Corp., added:
" The Easy application of the CS-Protect Hydrogel being a ready-to-use product after removal from sterile packaging and unrequired further work steps eliminates any risk of contamination due to preparation and assembly of the product exclusion of another hygienic risk area within the treatment room. Also, no risk of wrong mixture especially wrong sequence and therefore no potential patient's missed treatments. "
Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:
" The predecessor product was acquired by Boston Scientific for $ 500 million (https://news.bostonscientific.com/2018-10-16-Boston-Scientific-Closes-Acquisition-of-Augmenix-Inc). We project the start of the production of CS-Protect Hydrogel in the U.S. market towards the first quarter of 2026."
Looking toward the future, CS Diagnostics Corp. is positioning itself for long-term growth with breakthrough innovations. As a listed entity on OTCQB, CS Diagnostics Corp. provides U.S. investors with access to a high-growth opportunity, ensuring long-term shareholder value by creating and executing impactful, market-leading solutions.
(0)
(0)